CymaBay Therapeutics (NASDAQ:CBAY) PT Set at $20.00 by Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald set a $20.00 target price on CymaBay Therapeutics (NASDAQ:CBAY) in a report published on Wednesday morning, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Evercore ISI restated a buy rating and issued a $15.00 target price on shares of CymaBay Therapeutics in a research note on Wednesday, August 14th. B. Riley set a $7.00 target price on CymaBay Therapeutics and gave the company a hold rating in a research note on Monday, June 17th. ValuEngine upgraded CymaBay Therapeutics from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. BidaskClub downgraded CymaBay Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, July 30th. Finally, Stifel Nicolaus began coverage on CymaBay Therapeutics in a research note on Monday, June 24th. They issued a buy rating and a $14.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $14.09.

CymaBay Therapeutics stock traded up $0.06 during trading hours on Wednesday, reaching $5.63. 798,758 shares of the company’s stock were exchanged, compared to its average volume of 892,861. The company has a quick ratio of 16.20, a current ratio of 16.20 and a debt-to-equity ratio of 0.01. The firm’s 50 day simple moving average is $5.86 and its 200 day simple moving average is $9.47. CymaBay Therapeutics has a twelve month low of $4.82 and a twelve month high of $14.00. The firm has a market capitalization of $386.79 million, a PE ratio of -4.47 and a beta of 1.26.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. Analysts anticipate that CymaBay Therapeutics will post -1.47 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of CymaBay Therapeutics by 9.8% in the 2nd quarter. BlackRock Inc. now owns 5,530,692 shares of the biopharmaceutical company’s stock valued at $39,600,000 after buying an additional 493,662 shares during the period. Vanguard Group Inc. lifted its position in CymaBay Therapeutics by 6.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,559,875 shares of the biopharmaceutical company’s stock valued at $25,488,000 after acquiring an additional 226,906 shares in the last quarter. Vivo Capital LLC lifted its position in CymaBay Therapeutics by 4.8% in the 2nd quarter. Vivo Capital LLC now owns 2,154,934 shares of the biopharmaceutical company’s stock valued at $15,429,000 after acquiring an additional 98,934 shares in the last quarter. Rock Springs Capital Management LP lifted its position in CymaBay Therapeutics by 25.9% in the 2nd quarter. Rock Springs Capital Management LP now owns 900,000 shares of the biopharmaceutical company’s stock valued at $6,444,000 after acquiring an additional 185,000 shares in the last quarter. Finally, Fosun International Ltd lifted its position in CymaBay Therapeutics by 5.3% in the 2nd quarter. Fosun International Ltd now owns 834,096 shares of the biopharmaceutical company’s stock valued at $5,935,000 after acquiring an additional 42,000 shares in the last quarter. Institutional investors own 98.58% of the company’s stock.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Recommended Story: Street Name

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.